JPRN-jRCT2080221806未知2 期
Phase II/III Clinical Trial of TO-203 -Efficacy and Safety Trial in Patients with HDM-induced Rhinitis
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 900
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 12age old 至 <= 64age old（—）
- 性别
- All
入选标准
- •(1) HDM-specific IgE antibodies >= Class 3
- •(2) Positive on HDM nasal provocation test
- •(3) Medical history of treatment for HDM-induced rhinitis
- •(4) Moderate or severe symptoms of HDM-induced rhinitis
排除标准
- •(1) Specific IgE antibodies >= Class 5 any of the following: cedar, cypress, alder, cocksfoot, ragweed, mugwort, Japanese hop, cockroach, Candida, Aspergillus, Alternaria, dog hair, or cat hair
- •(2) Allergic rhinitis symptoms with class 2 to 4 in the specific IgE antibodies any of the following: cocksfoot, ragweed, mugwort, Japanese hop, cockroach, Candida, Aspergillus, Alternaria, dog hair, or cat hair
- •(3) Class 2 to 4 in the specific IgE antibody to dog hair or cat hair, and no rhinitis symptoms, but constantly exposed to the relevant animal (e.g., pet parenting at home, working at a pet shop)
- •(4) Patients who received immunotherapy with HDM allergen-containing products (e.g., house dust) for at least 1 month during 5 years before the first day of observation.
- •(5) Patients who are on immunotherapy other than HDM allergen-containing products on the first day of observation.
研究者
相似试验
未知
2 期
Phase II/III Clinical Trial of TO-203 -Efficacy and Safety Trial in Patients with HDM-induced AsthmaJPRN-jRCT2080221805TORII PHARMACEUTICAL CO., LTD.900
未知
3 期
Phase III Clinical Trial of TO-194SL - Efficacy and Safety Evaluation in Patients with Japanese Cedar PollinosisJapanese cedar pollinosisJPRN-jRCT2080221222TORII PHARMACEUTICAL CO., LTD.440
未知
1 期
Phase I Clinical Trial of TO-203 - Safety Trial in Patients with HDM (House Dust Mite)-induced AsthmaHDM-induced asthmaJPRN-jRCT2080221584TORII PHARMACEUTICAL CO., LTD.48
已完成
3 期
TO-208 Phase III Clinical StudyMolluscum ContagiosumJPRN-jRCT2041220039Kaneko Shinya300
进行中（未招募）
不适用
A phase II-III trial assessing the efficacy and safety of three doses of the ALK HDM tablet in house dust mite allergic subjects. - NDsubjects suffering from house dust mite allergyMedDRA version: 8.1Level: LLTClassification code 10057631Term: House dust allergyEUCTR2006-001795-20-ITALK-ABELLO800